Company Interview / Cyclopharm on the cusp of capturing the US market

James McBrayer CEO of Cyclopharm (ASX: CYC) discusses the drivers of future growth for Cyclopharm, and the company's expansion into the US market, plus the potential uses of AI in the business in the near future.

Cyclopharm is targeting between 250 and 300 installations by 2026. James McBrayer explains how its unique annuity model drives robust revenue generation.

*The information contained in this event is general in nature and is not intended as advice. 

Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD